Molbio Diagnostics IPO Targets ₹940 Crore for Growth and Stake Reduction

Molbio Diagnostics, a leader in molecular diagnostics, has announced plans to raise ₹940 crore through an upcoming Initial Public Offering (IPO). The company aims to gather ₹200 crore from a fresh issue to bolster its capital expenditures, while the remaining ₹740 crore will come from an offer for sale, leading to a reduction in promoter stake.

Strategic Financial Goals

The IPO will see the promoter group's stake in Molbio Diagnostics decrease from 46.6% to 43%. This move is part of a broader strategy to attract high-risk investors seeking long-term growth opportunities. The company operates six manufacturing sites across India and serves over 90 countries, providing diagnostic solutions to government health programs, laboratories, hospitals, and international healthcare organizations.

Molbio's flagship product, the 'Truenat' platform, is a portable diagnostic system that delivers accurate results within an hour, particularly beneficial for resource-limited settings. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, alongside radiology, digital pathology, and breast health screening solutions.

Revenue and Market Position

Financially, Molbio has shown robust growth, with revenue from operations rising 31.5% annually to ₹1,445.7 crore between FY24 and FY26. The net profit also surged by 40.2% annually, reaching ₹164.1 crore. The company's EBITDA margin improved to 22.6% in FY26 from 22% in FY24, reflecting operational efficiency.

Approximately 74% of Molbio's revenue is derived from the sale of test kits, with tuberculosis diagnostic kits alone contributing 70% of this segment. The company's reliance on a few key clients for over half of its revenue indicates a significant concentration risk, which potential investors should consider.

Valuation and Market Comparisons

Molbio's IPO valuation demands a price-earnings (P/E) multiple of up to 57, a figure that positions it within the range of other healthcare diagnostics and medical device companies in India. While it lacks a directly comparable listed peer, companies like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre trade at P/E multiples between 54 and 81.

Incorporated in 2000, Molbio has established itself as a provider of diagnostic solutions for both infectious and non-communicable diseases. The company derives over four-fifths of its revenue from government and international aid agencies, underscoring its significant role in global healthcare diagnostics.